zolmitriptan ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
serotonin (5-HT1) receptor agonists, sumatriptan derivatives 2869 139264-17-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • zolmitriptan
  • zipton
  • zominat
  • zomigoro
  • 311C90
an antimigraine compound; a serotonin (5HT)-1D receptor agonist
  • Molecular weight: 287.36
  • Formula: C16H21N3O2
  • CLOGP: 1.29
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 2
  • TPSA: 57.36
  • ALOGS: -3.18
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2.50 mg N
2.50 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 20 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 8 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.50 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 45 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.80 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 6.70 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.75 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.60 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 25, 1997 FDA IPR

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Migraine 158.42 15.67 127 9216 103219 63376460
Medication overuse headache 108.13 15.67 25 9318 807 63478872
Skin candida 68.43 15.67 20 9323 1635 63478044
Mastoiditis 58.33 15.67 16 9327 1039 63478640
Vascular malformation 52.49 15.67 12 9331 368 63479311
Paranasal cyst 51.67 15.67 12 9331 395 63479284
Headache 48.11 15.67 202 9141 633039 62846640
Antibody test positive 43.50 15.67 16 9327 2691 63476988
Monocyte count abnormal 42.41 15.67 9 9334 194 63479485
Infrequent bowel movements 37.85 15.67 12 9331 1290 63478389
Reversible cerebral vasoconstriction syndrome 36.49 15.67 14 9329 2644 63477035
Temperature intolerance 35.71 15.67 20 9323 8944 63470735
Depression 34.66 15.67 84 9259 196408 63283271
Urticaria chronic 31.80 15.67 9 9334 656 63479023
Lymphocyte count abnormal 31.15 15.67 9 9334 706 63478973
Vertigo 30.90 15.67 41 9302 59846 63419833
Nervous system disorder 30.68 15.67 24 9319 18742 63460937
Dyspnoea exertional 29.16 15.67 40 9303 60262 63419417
Blood thyroid stimulating hormone normal 28.84 15.67 6 9337 117 63479562
Polymenorrhagia 27.14 15.67 5 9338 50 63479629
Tuberculosis 26.68 15.67 18 9325 11193 63468486
Otitis media 25.35 15.67 13 9330 4878 63474801
Drug abuser 25.09 15.67 11 9332 2912 63476767
Thunderclap headache 25.08 15.67 6 9337 225 63479454
Colitis ischaemic 25.02 15.67 17 9326 10691 63468988
Oligohydramnios 24.81 15.67 14 9329 6352 63473327
Neutropenic sepsis 24.68 15.67 20 9323 16418 63463261
Oral herpes 23.86 15.67 24 9319 26050 63453629
Burns third degree 23.48 15.67 6 9337 296 63479383
Tuberculin test positive 23.16 15.67 11 9332 3500 63476179
Vitreous detachment 21.97 15.67 9 9334 2018 63477661
Insomnia 20.56 15.67 74 9269 215178 63264501
Dizziness 19.61 15.67 119 9224 429806 63049873
Mouth ulceration 19.23 15.67 24 9319 32960 63446719
Tension headache 19.12 15.67 11 9332 5175 63474504
Dust allergy 18.46 15.67 6 9337 698 63478981
Therapy partial responder 18.22 15.67 14 9329 10644 63469035
Myalgia 18.12 15.67 55 9288 146474 63333205
Arthropathy 18.09 15.67 6 9337 234786 63244893
Prinzmetal angina 17.98 15.67 6 9337 758 63478921
Renal infarct 17.66 15.67 7 9336 1440 63478239
Broad ligament tear 17.64 15.67 3 9340 18 63479661
Palpitations 17.54 15.67 46 9297 112724 63366955
Nausea 17.47 15.67 197 9146 854274 62625405
Nasal oedema 17.32 15.67 7 9336 1515 63478164
Serotonin syndrome 16.93 15.67 21 9322 28661 63451018
Patient isolation 16.38 15.67 3 9340 29 63479650
Carotid artery dissection 16.01 15.67 4 9339 180 63479499
Foetal hypokinesia 15.98 15.67 5 9338 515 63479164
Hemianopia 15.80 15.67 6 9337 1101 63478578
Dysphagia 15.72 15.67 38 9305 88547 63391132
Muscle discomfort 15.72 15.67 4 9339 194 63479485

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Paraesthesia 41.21 31.63 25 1027 64147 34891732
Therapy partial responder 40.69 31.63 14 1038 9602 34946277
Craniosynostosis 37.95 31.63 7 1045 373 34955506
Medication overuse headache 37.50 31.63 6 1046 136 34955743
Migraine 35.88 31.63 15 1037 17463 34938416

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Migraine 177.62 17.18 113 8488 87380 79648407
Medication overuse headache 130.38 17.18 28 8573 884 79734903
Skin candida 65.52 17.18 19 8582 2068 79733719
Headache 62.78 17.18 183 8418 653589 79082198
Mastoiditis 55.66 17.18 16 8585 1688 79734099
Vascular malformation 55.65 17.18 12 8589 386 79735401
Paranasal cyst 54.05 17.18 12 8589 443 79735344
Therapy partial responder 49.60 17.18 28 8573 17369 79718418
Reversible cerebral vasoconstriction syndrome 38.82 17.18 14 8587 3043 79732744
Burns third degree 37.84 17.18 9 8592 452 79735335
Depression 37.13 17.18 76 8525 216714 79519073
Insomnia 35.17 17.18 80 8521 245090 79490697
Renal infarct 32.96 17.18 12 8589 2679 79733108
Blood thyroid stimulating hormone normal 30.60 17.18 6 8595 119 79735668
Polymenorrhagia 28.78 17.18 5 8596 49 79735738
Tuberculin test positive 26.76 17.18 11 8590 3397 79732390
Otitis media 26.44 17.18 13 8588 6093 79729694
Nervous system disorder 25.52 17.18 22 8579 26834 79708953
Palpitations 24.81 17.18 47 8554 126563 79609224
Colitis ischaemic 24.25 17.18 17 8584 15342 79720445
Drug abuser 23.67 17.18 12 8589 6001 79729786
Thunderclap headache 23.58 17.18 6 8595 399 79735388
Paraesthesia 23.58 17.18 56 8545 176267 79559520
Temperature intolerance 23.36 17.18 14 8587 9691 79726096
Dust allergy 23.19 17.18 8 8593 1528 79734259
Nausea 23.09 17.18 179 8422 957017 78778770
Nasal oedema 22.28 17.18 8 8593 1716 79734071
Vertigo 22.12 17.18 32 8569 69050 79666737
Antibody test positive 21.88 17.18 9 8592 2783 79733004
Meningoencephalitis bacterial 21.35 17.18 5 8596 235 79735552
Dysphagia 21.10 17.18 43 8558 122093 79613694
Throat tightness 20.90 17.18 20 8581 27887 79707900
Trigemino-cardiac reflex 20.78 17.18 5 8596 264 79735523
Vitreous detachment 20.18 17.18 8 8593 2251 79733536
Disturbance in attention 19.99 17.18 26 8575 50775 79685012
Dry eye 19.60 17.18 22 8579 36909 79698878
Neutropenic sepsis 19.53 17.18 19 8582 27045 79708742
Nasal discharge discolouration 19.33 17.18 8 8593 2513 79733274
Mouth ulceration 18.90 17.18 22 8579 38372 79697415
Bronchial obstruction 18.61 17.18 8 8593 2760 79733027
Vasospasm 17.48 17.18 6 8595 1128 79734659
Coronary artery dissection 17.43 17.18 6 8595 1138 79734649

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N02CC03 NERVOUS SYSTEM
ANALGESICS
ANTIMIGRAINE PREPARATIONS
Selective serotonin (5HT1) agonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D058825 Serotonin 5-HT1 Receptor Agonists
MeSH PA D018490 Serotonin Agents
MeSH PA D017366 Serotonin Receptor Agonists
CHEBI has role CHEBI:35472 anti-inflammatory drugs
CHEBI has role CHEBI:35941 serotonin agonists
FDA MoA N0000175763 Serotonin 1b Receptor Agonists
FDA MoA N0000175764 Serotonin 1d Receptor Agonists
FDA EPC N0000175765 Serotonin-1b and Serotonin-1d Receptor Agonist

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Migraine indication 37796009 DOID:6364
Myocardial infarction contraindication 22298006 DOID:5844
Hypertensive disorder contraindication 38341003 DOID:10763
Hemiplegic migraine contraindication 59292006
Cerebral arteriosclerosis contraindication 65312002
Wolff-Parkinson-White pattern contraindication 74390002 DOID:384
Vascular insufficiency of intestine contraindication 82196007
Prinzmetal angina contraindication 87343002
Kidney disease contraindication 90708001 DOID:557
Angina pectoris contraindication 194828000
Cerebrovascular accident contraindication 230690007
Disease of liver contraindication 235856003 DOID:409
Transient ischemic attack contraindication 266257000 DOID:224
Raynaud's phenomenon contraindication 266261006
Cerebral ischemia contraindication 287731003
Cardiovascular event risk contraindication 395112001
Peripheral vascular disease contraindication 400047006
Disorder of coronary artery contraindication 414024009
Myocardial ischemia contraindication 414795007 DOID:3393
Hypertensive urgency contraindication 443482000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.47 acidic
pKa2 8.28 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
5-hydroxytryptamine receptor 1D GPCR AGONIST Ki 8.90 WOMBAT-PK CHEMBL
5-hydroxytryptamine receptor 1B GPCR AGONIST Ki 7.70 WOMBAT-PK CHEMBL
5-hydroxytryptamine receptor 1E GPCR Ki 7.70 WOMBAT-PK
5-hydroxytryptamine receptor 1A GPCR Ki 6.60 WOMBAT-PK
5-hydroxytryptamine receptor 1F GPCR Ki 7.45 WOMBAT-PK
D(2) dopamine receptor GPCR Kd 10.40 CHEMBL
D(1A) dopamine receptor GPCR Kd 9.52 CHEMBL
Adrenergic receptor alpha-2 GPCR Kd 8.15 CHEMBL

External reference:

IDSource
4021094 VUID
N0000148550 NUI
D00415 KEGG_DRUG
4021094 VANDF
C0528166 UMLSCUI
CHEBI:10124 CHEBI
CHEMBL1185 ChEMBL_ID
DB00315 DRUGBANK_ID
C089750 MESH_SUPPLEMENTAL_RECORD_UI
60857 PUBCHEM_CID
60 IUPHAR_LIGAND_ID
7408 INN_ID
2FS66TH3YW UNII
135775 RXNORM
11471 MMSL
52759 MMSL
5712 MMSL
d04253 MMSL
006460 NDDF
108406003 SNOMEDCT_US
363582006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Zolmitriptan Human Prescription Drug Label 1 16571-803 TABLET, FILM COATED 2.50 mg ORAL ANDA 25 sections
Zolmitriptan Human Prescription Drug Label 1 16571-804 TABLET, FILM COATED 5 mg ORAL ANDA 25 sections
ZOMIG HUMAN PRESCRIPTION DRUG LABEL 1 21695-955 SPRAY, METERED 5 mg NASAL NDA 28 sections
Zolmitriptan Human Prescription Drug Label 1 27241-021 TABLET 2.50 mg ORAL ANDA 24 sections
Zolmitriptan Human Prescription Drug Label 1 27241-022 TABLET 5 mg ORAL ANDA 24 sections
ZOLMITRIPTAN HUMAN PRESCRIPTION DRUG LABEL 1 31722-458 TABLET, FILM COATED 2.50 mg ORAL ANDA 19 sections
ZOLMITRIPTAN HUMAN PRESCRIPTION DRUG LABEL 1 31722-459 TABLET, FILM COATED 5 mg ORAL ANDA 19 sections
zolmitriptan HUMAN PRESCRIPTION DRUG LABEL 1 45802-711 SPRAY 5 mg NASAL ANDA 26 sections
Zolmitriptan Human Prescription Drug Label 1 46708-181 TABLET, ORALLY DISINTEGRATING 2.50 mg ORAL ANDA 25 sections
Zolmitriptan Human Prescription Drug Label 1 46708-181 TABLET, ORALLY DISINTEGRATING 2.50 mg ORAL ANDA 25 sections
Zolmitriptan Human Prescription Drug Label 1 46708-182 TABLET, ORALLY DISINTEGRATING 5 mg ORAL ANDA 25 sections
Zolmitriptan Human Prescription Drug Label 1 46708-182 TABLET, ORALLY DISINTEGRATING 5 mg ORAL ANDA 25 sections
Zolmitriptan Human Prescription Drug Label 1 46708-462 TABLET, FILM COATED 2.50 mg ORAL ANDA 25 sections
Zolmitriptan Human Prescription Drug Label 1 46708-462 TABLET, FILM COATED 2.50 mg ORAL ANDA 25 sections
Zolmitriptan Human Prescription Drug Label 1 46708-463 TABLET, FILM COATED 5 mg ORAL ANDA 25 sections
Zolmitriptan Human Prescription Drug Label 1 46708-463 TABLET, FILM COATED 5 mg ORAL ANDA 25 sections
Zolmitriptan Human Prescription Drug Label 1 50742-625 TABLET, FILM COATED 2.50 mg ORAL ANDA 25 sections
Zolmitriptan Human Prescription Drug Label 1 50742-626 TABLET, FILM COATED 5 mg ORAL ANDA 25 sections
Zolmitriptan Human Prescription Drug Label 1 55700-943 TABLET 2.50 mg ORAL ANDA 24 sections
Zolmitriptan Human Prescription Drug Label 1 55700-943 TABLET 2.50 mg ORAL ANDA 24 sections
Zolmitriptan Human Prescription Drug Label 1 55700-944 TABLET 5 mg ORAL ANDA 24 sections
Zolmitriptan Human Prescription Drug Label 1 55700-944 TABLET 5 mg ORAL ANDA 24 sections
Zolmitriptan HUMAN PRESCRIPTION DRUG LABEL 1 59746-432 TABLET, FILM COATED 2.50 mg ORAL ANDA 25 sections
Zolmitriptan HUMAN PRESCRIPTION DRUG LABEL 1 59746-433 TABLET, FILM COATED 5 mg ORAL ANDA 25 sections
Zolmitriptan OD HUMAN PRESCRIPTION DRUG LABEL 1 59746-461 TABLET, ORALLY DISINTEGRATING 2.50 mg ORAL ANDA 26 sections
Zolmitriptan OD HUMAN PRESCRIPTION DRUG LABEL 1 59746-462 TABLET, ORALLY DISINTEGRATING 5 mg ORAL ANDA 26 sections
ZOMIG HUMAN PRESCRIPTION DRUG LABEL 1 60846-2383 TABLET, FILM COATED 2.50 mg ORAL ANDA 26 sections
ZOMIG HUMAN PRESCRIPTION DRUG LABEL 1 60846-2384 TABLET, FILM COATED 5 mg ORAL ANDA 26 sections
Zolmitriptan HUMAN PRESCRIPTION DRUG LABEL 1 63548-0101 TABLET, FILM COATED 2.50 mg ORAL ANDA 25 sections
Zolmitriptan HUMAN PRESCRIPTION DRUG LABEL 1 63548-0101 TABLET, FILM COATED 2.50 mg ORAL ANDA 25 sections